XK and influenza: Currently, the only FDA-approved vaccine against H5N1 has serious limitations, particularly as it has to be given twice and requires substantially higher vaccine concentrations to achieve a moderate level of efficacy compared to conventional influenza vaccines.21,22 Conventional vaccines utilizing the HA and NA of H5N1 viruses have been poorly immunogenic and have safety and production issues (reviewed in ref. 23).